European Journal of Psychotraumatology
2024
Jerome Herpers, Natalie Maximets, Noah N N van Dongen et al.
7 citations
Introduction: The positive results of MDMA from Phase 2 and 3 clinical trials in MDMA-assisted therapy (MDMA-AT) for the treatment of post-traumatic stress disorder (PTSD) call for a critical evaluation of its regulatory status within the European mental healthcare system. This is driven by the recent submission of MDMA-AT for FDA approval in the United States. Unless coordinated efforts in the...
LGBT health
2024
Ziad Saade, Brady D. Hanshaw, Alex S Keuroghlian
3 citations
Sexually and gender diverse (SGD) populations experience an increased prevalence and severity of posttraumatic stress disorder (PTSD) compared with the general population. Minority stress theory contextualizes this increased disease burden by outlining how stigma and discrimination (e.g., homophobia and transphobia) contribute to worse mental health outcomes. The standard-of-care...
PLoS One
2024
Filip Stanicic, Vladimir Zah, Dimitrije Grbic et al.
4 citations
To explore the cost-effectiveness of midomafetamine-assisted therapy (MDMA-AT) compared to placebo with therapy (PT) in US healthcare settings. A health state-transition model was used to analyze the cost-effectiveness of MDMA-AT for treating patients with chronic PTSD of moderate or higher severity. Both treatment arms consisted of 3 preparation (90-min), 3 interventional (8-h), and 9...
Frontiers in Psychology
2024
Kelley C O'Donnell, Lauren Okano, Michael Alpert et al.
Results from multiple recent studies support further evaluation of 3,4-methylenedioxymethamphetamine (MDMA) in conjunction with psychotherapy (i.e., MDMA-Assisted Therapy) in the treatment of post-traumatic stress disorder (PTSD). In two Phase 3 trials, MDMA-Assisted Therapy comprised a short-term, intensive psychotherapy that included three sessions directly facilitated by MDMA (referred to as...
Journal of Psychedelic Studies
December 14, 2023
Ann M. Inouye, Aaron Wolfgang, Lianne T. Philhower
1 citation
AbstractAssociated with high-risk behavior, borderline personality disorder (BPD) remains one of the field's most misunderstood, misdiagnosed, and stigmatized conditions. Individuals with BPD are frequently labeled as treatment-resistant patients. Furthermore, 25–58% of BPD individuals have a comorbid diagnosis of post-traumatic stress disorder (PTSD), and BPD may be conceptualized as a...
Journal of psychopharmacology (Oxford, England)
December 1, 2023
Brian J Gully, Erica Eaton, Christy Capone et al.
12 citations
Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) frequently co-occur in patients who have experienced trauma. This comorbidity leads to a vicious cycle where PTSD symptoms beget heavy drinking and vice versa. There are no FDA-approved medications to treat PTSD-AUD; therefore, individuals suffering from this comorbidity are treated with medication approved to treat the...
AJN American Journal of Nursing
November 21, 2023
MDMA therapy for PTSD. Those suffering from posttraumatic stress disorder (PTSD) may have a new treatment option—psychedelic therapy. In a confirmatory randomized controlled trial with 104 participants, researchers found that 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy reduced symptoms and functional impairment in people with moderate to severe PTSD. Their findings add to a...
ACS Chemical Neuroscience
November 15, 2023
L Jacob Flameling, Jacob S Aday, Michiel van Elk
ADVERTISEMENT RETURN TO ARTICLES ASAPPREVViewpointNEXTExpectancy Effects Cannot Be Neglected in MDMA-Assisted Therapy ResearchL. Jacob FlamelingL. Jacob FlamelingInstitute of Psychology, Leiden University, Leiden 2333 AK, The NetherlandsMore by L. Jacob Flamelinghttps://orcid.org/0000-0002-1425-1180, Jacob S. AdayJacob S. AdayDepartment of Anesthesiology, University of Michigan, Ann Arbor,...
Diseases
November 3, 2023
Kainat Riaz, Sejal Suneel, Mohammad Hamza Bin Abdul Malik et al.
16 citations
Post-traumatic stress disorder (PTSD) is a debilitating mental health disorder that causes significant dysfunction in individuals. Currently, there are many approved pharmacotherapy and psychotherapy treatment options for PTSD, but unfortunately, half of the patients do not respond to traditional therapies. In this article, we review clinical trials and research on...
Nature Medicine
October 1, 2023
Jennifer Mitchell, Marcela Ot’alora G., Bessel Van der Kolk et al.
400 citations
This multi-site, randomized, double-blind, confirmatory phase 3 study evaluated the efficacy and safety of 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) versus placebo with identical therapy in participants with moderate to severe post-traumatic stress disorder (PTSD). Changes in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total severity score (primary endpoint) and...